surmount-1 trial tirzepatide non-diabetic obesity weight loss Demonstrates 94% Diabetes Reduction, 22% in SURMOUNT -1 Study surmount-1 trial tirzepatide non-diabetic obesity

As Georgias premier compounding pharmacy, we are dedicated to helping patients achieve their wellness goals with expert guidance, high-quality medications, and compassionate care

For instance, some providers exclude Zepbound for obesity treatment but will cover Mounjaro, which contains the same active ingredient, for diabetes management

A direct consequence of this is that the difference in efficacy between retatrutide and tirzepatide (approximately -7,8 points) must be weighed against this difference in tolerability and a discontinuation rate two to three times higher

Fritzer-Szekeres M, Blom HJ, Boers GHJ, Szekeres T, and Lubec B (1998)